TLR4 and Alzheimer disease: In parallel, our group recently demonstrated that the chronic systemic administration of a detoxified TLR4 ligand, which is a lipopolysaccharide derivative called monophosphoryl lipid A, potently decelerated AD-related pathology in a mouse model of AD, by significantly reducing cerebral Aβ deposits and ameliorating the cognitive functions of these mice [73].